News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Karie Danielle Keera Runcie, MD

Articles by Karie Danielle Keera Runcie, MD

Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.

Early Recurrence Post-Pembrolizumab Inspires Zanzalitinib Trial in ccRCC

ByKarie Danielle Keera Runcie, MD

July 31st 2025

Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.

Latest Updated Articles

Early Recurrence Post-Pembrolizumab Inspires Zanzalitinib Trial in ccRCC
July 31st 2025

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)